Worse overall, disease-free survival with V600E BRAF versus KRAS mutation in colorectal liver metastases
FRIDAY, May 18, 2018 (HealthDay News) — For patients undergoing resection of colorectal liver metastases (CRLM), the presence of the V600E BRAF mutation is associated with worse prognosis, according to a study published online May 16 in JAMA Surgery.
Georgios Antonios Margonis, M.D., Ph.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a cohort study to examine the prognostic association of BRAF mutations with survival and recurrence independently and compared with other prognostic determinants. Patients who underwent resection for CRLM with curative intent and had data on BRAF and KRAS mutational status were identified; 849 patients were included in the analyses.
The researchers found that 5.1 percent of patients had a mutated (mut) BRAF/wild-type (wt) KRAS (V600E and non-V600E) genotype, 56.5 percent had a wtBRAF/wtKRAS genotype, and 38.4 percent had a wtBRAF/mutKRAS genotype. On multivariable analysis, V600E, but not non-V600E, BRAF mutation was correlated with worse overall survival and disease-free survival (hazard ratios, 2.76 and 2.04, respectively). Compared with the KRAS mutations, the V600E BRAF mutation was more strongly associated with overall survival and disease-free survival (β for overall survival, 10.15 versus 2.94; β for disease-free survival, 7.14 versus 2.27).
“The presence of the V600E BRAF mutation was associated with worse prognosis and increased risk of recurrence,” the authors write.
Copyright © 2018 HealthDay. All rights reserved.
